催乳素瘤患者的诊疗方法
催乳素瘤是最常见的垂体瘤组织类型,微腺瘤多见于女性,大腺瘤多见于男性。高催乳素血症是两性低促性腺激素性性腺功能减退症的常见原因,诊断需单次催乳素测定和垂体影像学检查,但钩状效应和大催乳素血症等实验室伪影可干扰诊断。多巴胺激动剂(主要为卡麦角林)是首选治疗,可控制疾病、恢复生育力并治愈三分之一患者,从而允许停药;妊娠和绝经可促进催乳素自发下降并提前卡麦角林停药。对卡麦角林抵抗者,手术和/或放疗有指征;侵袭性/增殖性肿瘤的抵抗可能提示生物学侵袭性,需替莫唑胺等替代治疗。
要点
- 微催乳素瘤多见于女性,大催乳素瘤多见于男性。
- 诊断采用单次催乳素测定和垂体影像学检查,需注意钩状效应和大催乳素血症。
- 多巴胺激动剂(主要为卡麦角林)是首选治疗,可治愈三分之一患者并允许停药。
核心结论
- 多巴胺激动剂(主要为卡麦角林)是催乳素瘤的首选治疗,可控制疾病、恢复两性生育力并治愈三分之一患者,从而允许停药。
研究设计与样本
- 本文为综述,回顾催乳素瘤的不同方面并讨论常见临床情况下的处理方法。
主要发现
- 微催乳素瘤在女性中多见,大催乳素瘤在男性中多见。
- 高催乳素血症是两性低促性腺激素性性腺功能减退症的常见原因,可促使患者因性腺功能减退(不孕、稀发月经/闭经、阳痿、骨质疏松/骨量减少)就诊,男性还常因占位效应症状(垂体功能减退、视力丧失、视交叉受压、颅神经缺损、头痛)就诊。
- 诊断检查包括单次催乳素测定和垂体影像学检查,但钩状效应和大催乳素血症等实验室伪影可使诊断复杂化或延迟。
- 妊娠和绝经可能促进催乳素自发下降,并提前女性卡麦角林停药。
- 对卡麦角林抵抗且增加药物剂量至最大耐受剂量仍不能克服,或患者个人选择手术时,有手术和/或放疗指征。
临床怎么用
- 多巴胺激动剂(主要为卡麦角林)是催乳素瘤的首选治疗。
- 对卡麦角林抵抗且增加剂量至最大耐受剂量仍不能克服,或患者个人选择手术时,有手术和/或放疗指征。
- 对未控制患者,可提供新的医学方法,但迄今经验仍非常少。
局限性
- 对未控制患者的新医学方法迄今收集的经验仍非常少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prolactinomas are the most common pituitary tumor histotype, with microprolactinomas being prevalent in women and macroprolactinomas in men. Hyperprolactinemia is among the most common causes of hypogonadotropic hypogonadism in both sexes, prompting medical advice for hypogonadism (infertility, oligo-amenorrhea, impotence, osteoporosis/osteopenia) in both sexes, and for signs and symptoms of mass effects (hypopituitarism, visual loss, optic chiasm compression, cranial nerve deficits, headaches) predominantly in men. Diagnostic workup involves a single prolactin measurement and pituitary imaging, but some laboratory artifacts (ie, the "hook effect" and macroprolactin) can complicate or delay the diagnosis. The treatment of choice for prolactinomas is represented by dopamine agonists, mainly cabergoline, which are able to induce disease control, restore fertility in both sexes, and definitively cure one-third of patients, thus permitting treatment discontinuation. Pregnancy and menopause may promote spontaneous prolactin decline and anticipate cabergoline discontinuation in women. Surgery and/or radiotherapy are indicated in case of resistance to cabergoline not overcome by the increase in drug dose up to the maximally tolerated or the patient's personal choice of surgery. The evidence of resistance to cabergoline in invasive and proliferative tumors may indicate biological aggressiveness, thus requiring alternative therapeutic approaches mainly based on temozolomide use as monotherapy or combined with radiotherapy. In uncontrolled patients, new medical approaches (alternative hormonal treatments, cytotoxic drugs, peptide receptor radionuclide therapy, mTOR/Akt inhibitors, tyrosine kinase inhibitors, or immunotherapy) may be offered but the experience collected to date is still very scant. This article reviews different facets of prolactinomas and discusses approaches to the condition in more common clinical situations.
引用
- Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab. 2023. PMID: 36974474. doi:10.1210/clinem/dgad174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。